**Supplemental Table 1. Baseline characteristics (divided by baseline eGFR) (n=81).**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Group 1 n=40 | Group 2 n=41 | P value |
| Body weight (kg) | 80.8±19.3 | 81.8±19.7 | 0.83 |
| Body mass index (kg/m2) | 29.7±4.95 | 30.2±5.51 | 0.71 |
| HbA1c (%) | 8.30±1.27 | 8.28±1.13 | 0.93 |
| BUN (mg/dl) | 17.4±4.44 | 12.7±2.95 | <0.0001\* |
| Cre (mg/dl) | 0.84±0.19 | 0.62±0.16 | <0.0001\* |
| eGFR (mL/min/1.73 m2) | 65.6±11.2 | 101±24.3 | <0.0001\* |
| CCr (mL/min) | 103±36.8 | 164±45.0 | <0.0001\* |
| LDL-C (mg/dl) | 102±32.2 | 109±32.1 | 0.31 |
| HDL-C (mg/dl) | 49.3±15.3 | 51.4±12.7 | 0.50 |
| TG (mg/dl) | 129 (98, 222) | 161(118, 227) | 0.31 |
| UA (mg/dl) | 5.68±1.13 | 5.42±1.44 | 0.38 |

Mean ± standard deviation or medians (25th and 75th percentiles). CCr was calculated by Cockcroft & Gault equation.

P value were determined by paired t-test or Wilcoxon rank sum test.

Group 1: eGFR **<** 80.0 (mL/min/1.73 m2), Group 2: eGFR ≥ 80.0 (mL/min/1.73 m2)

**Supplemental Table 2. Mean changes from baseline in glycemic control, blood pressure, lipid profile, and renal function in patients receiving SGLT-2 inhibitors for 4 weeks (n=23).**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | standard value | baseline | 4 weeks | P-value |
| Body weight (kg) |  | 82.2±15.4 | 81.9±15.8 | 0.54 |
| Body mass index (kg/m2) |  | 29.0±3.41 | 28.9±3.33 | 0.44 |
| HbA1c (%) |  | 8.4 (7.3, 9.6) | 7.8 (6.9, 8.5) | <0.0001\* |
| eGFR (mL/min/1.73 m2) |  | 78.5 (66.4, 88.4) | 74.3 (68.0, 79.0) | 0.012\* |
| CCr (mL/min) |  | 125 (98.2, 149) | 118 (92.0, 143) | 0.010\* |
| SBP (mmHg) |  | 135±18.4 | 131±15.5 | 0.062 |
| DBP (mmHg) |  | 82.5±13.6 | 81.6±11.4 | 0.63 |
| LDL-C (mg/dl) |  | 83.6 (72.2, 113) | 75.2 (66, 87.6) | 0.12 |
| HDL-C (mg/dl) |  | 50.0±14.1 | 52.0±11.6 | 0.14 |
| TG (mg/dl) |  | 158 (95, 219) | 169 (94, 225) | 0.81 |
| UA (mg/dl) |  | 5.81±1.43 | 5.12±1.30 | 0.0018\* |
| Urinary albumin (mg/g Cre) | ≤ 18.6 | 17.0 (6.90, 187) | 13.1 (7.5, 94.9) | 0.77 |
| Urinary NAG ‡ (U/g Cre) | ≤ 5.6 | 6.02 (3.07, 8.99) | 6.33 (5.20, 10.9) | 0.053 |
| Urinary L-FABP § (µg/g Cre) | ≤ 8.4 | 2.70 (1.20, 5.80) | 3.00 (1.90, 4.00) | 0.10 |
| Urinary type IV collagen (µg/g Cre) | ≤ 7.3 | 5.10 (1.60, 6.90) | 5.30 (3.80, 6.70) | 0.024\* |
| Urinary　β2MG ¶　(µg/g Cre) | † | 78.5 (40.0, 179) | 92.6 (66.8, 173) | 0.57 |

Mean ± standard deviation or medians (25th and 75th percentiles). CCr was calculated by Cockcroft & Gault equation. † The reference value of β2 microglobulin was 11-253 μg/day in our hospital. We used the spot urine sample and the urinary excretion levels of β2 microglobulin were described as micrograms per gram of creatinine. P value were determined by paired t-test or Wilcoxon signed-rank test. ‡ NAG; N-acetyl-β-D-glucosaminidase, § L-FABP; Liver-type Fatty Acid Binding Protein, ¶ β2MG; β2 microglobulin.